Navigation Links
Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
Date:1/4/2008

- Studies to investigate safety and efficacy in treatment of multi-drug

resistant infections -

NEW HAVEN, Conn., Jan. 4 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a biopharmaceutical company focused on the development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced the enrolment of the first patients in two separate Phase 2 clinical trials. The studies will evaluate the safety and efficacy of RX-1741 in the treatment of Community-Acquired Pneumonia (CAP), and separately in the outpatient treatment of Uncomplicated Skin and Skin Structure Infections (uSSSI). RX-1741 is the Company's first antibiotic program developed using its proprietary technology platform.

RX-1741 is an oxazolidinone antibiotic that exhibits activity against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive organisms, and has demonstrated both greater spectrum and potency of activity than the currently marketed product of the same class, Zyvox(R) (linezolid). Discovered using proprietary knowledge of the three dimensional structure of a key area of the ribosome, the 50S subunit, Rib-X believes that RX-1741 will demonstrate a high level of effectiveness against resistant microbes.

"These two studies represent important milestones for Rib-X," said Dr. Susan Froshauer, President and CEO of Rib-X Pharmaceuticals. "RX-1741 is the first of many compounds that Rib-X intends to design and develop in response to the alarming growth of drug resistant microbial pathogens found both in the hospital and in the community. This MRSA-active agent will satisfy a critical need for physicians and their patients because current treatment options are very limited, particularly for orally active agents," said Dr. Froshauer.

CAP Study Design

The CAP study is a Phase 2, multicenter, randomized, double-blind study designed to evaluate the safety and efficacy
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
2. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
3. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
4. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
5. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
8. Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering
9. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2008)...e-FirstCall/ -- PURE Bioscience (Nasdaq:,PURE), cr...rogen citrate,(SDC), today reported revenues for t...which increased more than 340% compared with $336,... a loss from operations before taxes,of $(6,540,30...$(4,654,900), or $(0.19) per share, in the prior y...
(Date:10/15/2008)...FirstCall/ - GeneNews Limited (TSX: GEN),a compan...s for the early,detection of diseases and personal...s appointed Patrick Terry as its lead strategic ad...y(TM), the world,s fist blood-based,test to determ... Mr. Terry,is one of the co-founders of Genomic He...
(Date:10/14/2008)...gma-Aldrich,s leading MISSION(TM) shRNA ... /- Sigma-Aldrich (Nasdaq: SIAL ), a...Ai Consortium (TRC),proudly welcomes the Memorial...ship Program ( http://sigma-aldrich.com/rpp ). The...h access to cutting-edge products in,Sigma-Aldrich...
(Date:10/14/2008)...ss Results to Be Held at 9:00 A.M. -, EXTON, Pa.,...rporated,s,(Nasdaq: VPHM ) third quarter financia...Wednesday, October 29, 2008 before the open of the... conference call and live audio webcast at 9:00,a....ence call, ViroPharma,management will discuss the ...
Breaking Biology Technology:PURE Bioscience Reports Fourth Quarter and Year End Results 2PURE Bioscience Reports Fourth Quarter and Year End Results 3PURE Bioscience Reports Fourth Quarter and Year End Results 4PURE Bioscience Reports Fourth Quarter and Year End Results 5PURE Bioscience Reports Fourth Quarter and Year End Results 6PURE Bioscience Reports Fourth Quarter and Year End Results 7GeneNews appoints Patrick Terry as lead strategic advisor for U.S. commercialization of ColonSentry(TM) 2Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program 2Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program 3ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008 2
... Technology Network (WTN) just turned one! It is b...ee what we have accomplished in just 12 months of ...by Amazon and powered by Goggle) wistechnology.co... reach, and page views compared to other technolog...st. WTN is read beyond Wisconsin with 30% of its, ...
...over Spirit, which bounced to a near pinpoint land...Saturday (Jan. 3) after a seven-month flight, prom...Madison scientists say. , ,John Valley, a UW-Madis...ducted isotopic analyses of meteorites believed to...onsiderably to our knowledge of Mars and whether o...
...,Lets start with the good in Midwest biotech in 20...ormance of the publicly traded Midwest biotech com... Index, which evaluates the top 20 biotech stocks ...tellar performance of the Nasdaq and Amex Biotech ...lly ticked up even more in the last trading days o...
.... - GE Medical Systems and University Community H...ealth network based in Tampa, Florida have announc...dvanced heart hospitals. GE Medical Systems will...scular hospital, designed to deliver cardiovascula...hnology, when it opens in the spring of 2005. , ,...
Other Biology Technology:WTN's First Year 2The Good, Bad, Ugly of Midwest Biotech in 2003 2The Good, Bad, Ugly of Midwest Biotech in 2003 3GE Medical Enables Digital Heart Hospital 2GE Medical Enables Digital Heart Hospital 3
(Date:10/14/2008)...es for finding life on other planets and in extrem...State,s new astrobiology initiative under a five-y...Signatures of Life from Earth and Beyond." , Chr...ces, will lead an interdisciplinary team to develo...r biological signatures in relevant ecosystems in ...
(Date:10/14/2008)...e is available in Spanish . , An interdiscipli...at the Institute for Research in Biomedicine (IRB ...Catal d,Investigaci Qumica" (ICIQ, Tarragona), hav...tain protein p53 stable even when it presents cert...r. Giralt, head of the Chemistry and Molecular Pha...
(Date:10/14/2008)... 14, 2008Three years after Hurricane Katrina devas...ses of the destruction of the city,s floodwall sys...Entomologist (Vol. 54, No. 3) suggests that Formo... Author Gregg Henderson, a professor at the Louisi... subterranean termites (Coptotermes formosanus Shi...
(Date:10/14/2008)...r Health and Nutrition announced the publication o...en associated with the health benefits of red wine...ts. In the September 24 edition of the Journal o...ort that cocoa powder, baking chocolate and dark c...l, a naturally occurring antioxidant. , "This s...
Breaking Biology News(10 mins):Penn State receives new NASA astrobiology grant 2Penn State receives new NASA astrobiology grant 3Design of a compound that stabilizes the main natural suppressor of tumors 2Did termites help Katrina destroy New Orleans floodwalls? 2Resveratrol, red wine compound linked to health, also found in dark chocolate and cocoa 2HealthSouth Issues Statement on Medicare Bill and 75 25 Rule 8625 1HealthSouth Issues Statement on Medicare Bill and 75 25 Rule 8625 2Kiwa Signs Letter of Intent with Huaxing Animal Medicine 2338 1Kiwa Signs Letter of Intent with Huaxing Animal Medicine 2338 2Kiwa Signs Letter of Intent with Huaxing Animal Medicine 2338 3ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease 2335 1ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease 2335 2ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease 2335 3ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease 2335 4Human embryonic stem cell lines created that avoid immune rejection 8621 1Human embryonic stem cell lines created that avoid immune rejection 8621 2
...r all its promise, the prospect of using nanoparti...cts has raised concerns about possible harmful eff... University of Michigan are addressing those conce...icles damage cell membranes---enough to cause cell...revented. , "If you,re inventing these sorts of ma...
...ees in the world¹s most productive forests -- fore... tend to die young, according to a U.S. Geological...f the journal Ecology Letters. This discovery coul... to ongoing and future environmental changes. , "O...the world¹s most productive forests may be those l...
...ltiple sclerosis (MS) can be an unpredictable dise...acks healthy nerve cells and disrupts normal nerve...mptoms—including tingling, paralysis, pain, fatigu...y or in combination, sporadically or persistently....flare-ups are common in the majority of patients. ...
...number of articles explore the use of positron emi...onsurgical techniques that open the door to unders...issue of the Society of Nuclear Medicine,s Journal...nimal imaging "is the ability to carry out many st..." said SNM member Michael J. Welch, Ph.D., co-auth...
Other Biology News:Probing the promise and perils of nanoparticles 2Live fast, die young true for forests too 2Gene Signatures Predict Interferon Response For Multiple Sclerosis Patients 2Use of PET can reduce, may eliminate more strenuous drug development trials with animals 2Use of PET can reduce, may eliminate more strenuous drug development trials with animals 3Use of PET can reduce, may eliminate more strenuous drug development trials with animals 4
Rad51B
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies.
Biology Products: